Deutsche Tageszeitung - Pharma heavyweights clash over anti-obesity drug ads

Weather - Berlin 0°C

Pharma heavyweights clash over anti-obesity drug ads

HEALTH 21.07.2026

Pharma heavyweights clash over anti-obesity drug ads / Photo: © AFP/File

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments.

Change text size:

The Danish maker of Wegovy and Ozempic complained that the US group -- which makes rival weight-loss treatments Zepbound and Mounjaro -- "intentionally selected outdated studies" that compared Lilly's highest doses against lower doses of Novo Nordisk's medicines.

The US group's ads "deceptively (presented) those results as proof of broad, product-level superiority while burying or omitting critical clinical context," the Danish group said.

Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide.

The drugs are a financial windfall for each the pharmaceutical giants.

"As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions," said Novo Nordisk's general counsel, John F. Kuckelman.

"Healthcare companies have a responsibility to keep their public claims accurate and current -- ineffective, fine-print disclaimers do not fix the misleading impression created by major national campaigns."

The target of the Danish group's wrath is an advertising campaign that was "aired during recent, widely viewed global sporting broadcasts and on TikTok and Facebook, causing widespread confusion," it said.

Anti-obesity treatments mimic a hormone secreted by the intestines, GLP-1.

They can be used for weight loss and/or to treat type 2 diabetes, the most common form of the disease.

(I.Beryonev--DTZ)

Featured

NHS to test blood screening designed to detect 13 cancers earlier

More than 20,000 NHS patients across England are to be offered pioneering blood tests that could help doctors identify 13 different types of cancer at an earlier stage, potentially improving patients’ chances of successful treatment. The £8.

Seacliff Healthcare Seeks Specialist GP in Thirroul

Seacliff Healthcare, located in the Illawarra region of New South Wales, is seeking a Specialist General Practitioner to join its team. The practice, situated near Thirroul village station, currently supports five GPs and has capacity for additional medical staff with onsite pathology and allied health services.

India proposes more import entry points for drugs and medical devices

New Delhi The Union Health Ministry has proposed expanding the network of authorised import gateways for drugs, medical devices and cosmetics by adding several inland container depots, a special economic zone and an international airport to facilitate faster clearance and improve supply chain efficiency. The proposed amendment to Rule 43A of the Drugs Rules, 1945, seeks to include additional entry points in Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka, as reported by a gazette notification issued by the

Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise

Grace Griffin thought she had calculated her pregnancy expenses accurately until bills exceeded $9,000—more than triple her insurer’s estimate. Her experience highlights a systemic failure in healthcare transparency, as federal rules designed to provide accurate cost predictions remain unimplemented. With maternity billing codes set to change next year, experts urge parents to master insurance details and verify every bill.

Change text size: